Tiziana Life Sciences Ltd
TLSA2.420USD
+0.040+1.68%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
269.74MMarktkapitalisierung
--KGV TTM
mehr Informationen über Tiziana Life Sciences Ltd Unternehmen
Tiziana Life Sciences Ltd. is a United Kingdom-based clinical-stage biotechnology company that is specialized in the developing transformative therapies for neurodegenerative and neuroinflammatory. The Company’s clinical pipeline includes drug assets for secondary progressive multiple sclerosis, Alzheimer’s, and ALS. Its lead immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer’s and other CNS indications. Its Anti IL-6R mAb (TZLS-501), a fully human mAb binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune disease and cancer, reducing circulating levels of the IL-6 cytokine.
Unternehmensinformationen
BörsenkürzelTLSA
Name des UnternehmensTiziana Life Sciences Ltd
IPO-datumNov 20, 2018
CEOMr. Ivor Elrifi
Anzahl der mitarbeiter- -
WertpapierartOrdinary Share
GeschäftsjahresendeNov 20
Addresse- -
Stadt- -
BörseNASDAQ Capital Market Consolidated
Land- -
Postleitzahl- -
Telefon- -
Website- -
BörsenkürzelTLSA
IPO-datumNov 20, 2018
CEOMr. Ivor Elrifi
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Willy Jules Simon
Mr. Willy Jules Simon
Non-Executive Independent Director
Non-Executive Independent Director
8.25K
--
Mr. John P. Brancaccio, CPA
Mr. John P. Brancaccio, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Gabriele Marco Antonio Cerrone
Mr. Gabriele Marco Antonio Cerrone
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Ivor Elrifi
Mr. Ivor Elrifi
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Ms. Keeren Shah
Ms. Keeren Shah
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
--
--
Dr. William A. Clementi, Pharm.D.
Dr. William A. Clementi, Pharm.D.
Chief Development Officer
Chief Development Officer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Willy Jules Simon
Mr. Willy Jules Simon
Non-Executive Independent Director
Non-Executive Independent Director
8.25K
--
Mr. John P. Brancaccio, CPA
Mr. John P. Brancaccio, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Gabriele Marco Antonio Cerrone
Mr. Gabriele Marco Antonio Cerrone
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Ivor Elrifi
Mr. Ivor Elrifi
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Ms. Keeren Shah
Ms. Keeren Shah
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
--
--
Dr. William A. Clementi, Pharm.D.
Dr. William A. Clementi, Pharm.D.
Chief Development Officer
Chief Development Officer
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, Jun 14
Aktualisiert: Sat, Jun 14
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Cerrone (Gabriele M)
37.71%
Chernett (Jorey)
5.34%
Dauntless Investment Group, LLC
1.56%
Jane Street Capital, L.L.C.
0.15%
OMERS Administration Corporation
0.13%
Other
55.10%
Aktionäre
Aktionäre
Anteil
Cerrone (Gabriele M)
37.71%
Chernett (Jorey)
5.34%
Dauntless Investment Group, LLC
1.56%
Jane Street Capital, L.L.C.
0.15%
OMERS Administration Corporation
0.13%
Other
55.10%
Aktionärstypen
Aktionäre
Anteil
Individual Investor
43.06%
Investment Advisor
2.04%
Research Firm
0.26%
Investment Advisor/Hedge Fund
0.25%
Pension Fund
0.13%
Hedge Fund
0.04%
Other
54.22%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
68
51.04M
45.79%
+9.50M
2025Q1
69
45.10M
40.46%
+3.34M
2024Q4
64
40.33M
36.45%
-5.07M
2024Q3
58
41.30M
37.43%
-3.04M
2024Q2
51
40.27M
36.45%
-4.04M
2024Q1
48
40.16M
36.35%
-4.27M
2023Q4
52
45.25M
44.24%
+1.19M
2023Q3
58
45.24M
44.24%
+1.10M
2023Q2
54
45.32M
44.32%
+1.19M
2023Q1
53
45.06M
44.06%
+868.09K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Cerrone (Gabriele M)
42.04M
37.71%
+2.70M
+6.85%
Mar 31, 2025
Chernett (Jorey)
5.95M
5.34%
+5.95M
--
Jun 11, 2025
Dauntless Investment Group, LLC
1.74M
1.56%
+1.74M
--
Mar 31, 2025
Jane Street Capital, L.L.C.
167.54K
0.15%
+151.86K
+968.24%
Mar 31, 2025
OMERS Administration Corporation
144.90K
0.13%
+144.90K
--
Mar 31, 2025
HSBC Global Asset Management (UK) Limited
105.36K
0.09%
--
--
Mar 31, 2025
Morgan Stanley & Co. LLC
92.57K
0.08%
+18.20K
+24.47%
Mar 31, 2025
Zhang Financial LLC
96.26K
0.09%
+3.07K
+3.30%
Mar 31, 2025
Kovitz Investment Group Partners, LLC
79.36K
0.07%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
77.89K
0.07%
-167.84K
-68.30%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
Fidelity Nasdaq Composite Index ETF
0%
Fidelity Nasdaq Composite Index ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Oct 20, 2021
Merger
2<1
Oct 20, 2021
Merger
2<1
Oct 20, 2021
Merger
2<1
Oct 20, 2021
Merger
2<1
Jul 16, 2020
Split
1>2.5
Datum
Art
Verhältnis
Oct 20, 2021
Merger
2<1
Oct 20, 2021
Merger
2<1
Oct 20, 2021
Merger
2<1
Oct 20, 2021
Merger
2<1
Jul 16, 2020
Split
1>2.5
